Poly ADP-ribose polymerase inhibitors (PARPi) are used for patients with advanced prostate cancer bearing alterations in homologous recombination repair (HRR) genes. We sought to characterize HRR gene ...
PARIS--(BUSINESS WIRE)--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in ...
Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous ...
DNA double-strand breaks (DSBs) induced by ionizing radiation pose a major threat to cell survival. The cell can respond to the presence of DSBs through two major repair pathways: homologous ...
In patients unselected for homologous recombination repair (HRR) gene status, median overall survival (OS) improved from 37 months with the androgen receptor-pathway inhibitor (ARPI) alone to 45.8 ...
CTCF is an essential epigenetic regulator mediating chromatin insulation, long-range regulatory interactions, and the organization of large topological domains in the nucleus. Phenotypes of CTCF ...
Tokyo, Japan – Researchers from Tokyo Metropolitan University have been studying DNA repair by homologous recombination, where the RecA protein repairs breaks in double-stranded DNA by incorporating a ...
A recent study, undertaken by researchers at the Tokyo Metropolitan University and the Tokyo Metropolitan Institute of Medical Science (both Japan), unravels key steps in the process of homologous ...
Since targeting DNA repair pathways with PARP inhibitors is already used to treat breast and ovarian cancer, the researchers compared Lynparza with Xtandi (enzalutamide) or Zytiga (abiraterone acetate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback